28 Oct How Immunotherapy Is Changing Breast Cancer Treatment in the UAE
Cancer Care Notice: Immunotherapy is approved only for specific types and stages of breast cancer, and results described here reflect averages across groups of patients in clinical trials, not guarantees for any individual. Some uses discussed are still being studied. Treatment decisions should be made with your oncology team. If you are receiving immunotherapy, report new symptoms such as cough or shortness of breath, diarrhea, severe fatigue, rash, or yellowing of the skin or eyes to your care team promptly, as immune-related side effects can be serious.
Editorial Notice: This article is for general information and is not specific medical advice. Hospitals and providers named or linked in this article are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc.
Breast cancer remains the most commonly diagnosed cancer among women in the United Arab Emirates, accounting for nearly 40 percent of all female cancer cases, according to national registry data. While traditional treatments like chemotherapy, radiation, and surgery have long formed the backbone of care, a newer approach is reshaping outcomes for certain patients: immunotherapy. This treatment harnesses the body’s immune system to recognize and attack cancer cells, offering hope particularly for aggressive subtypes that have historically been difficult to treat.
The shift toward immunotherapy reflects a broader transformation in oncology, where precision medicine tailors treatment to the specific characteristics of each tumor. For breast cancer patients in Abu Dhabi and across the UAE, understanding how immunotherapy works, who benefits most, and how it fits into comprehensive care can inform better treatment decisions.
Understanding Immunotherapy for Breast Cancer
Unlike chemotherapy, which directly attacks rapidly dividing cells, immunotherapy works by helping the immune system recognize and attack cancer cells that would otherwise evade it. Cancer cells often express proteins that essentially tell immune cells to leave them alone. Immunotherapy drugs, particularly checkpoint inhibitors, block these signals and allow T-cells to mount an attack.
For breast cancer, immunotherapy has shown the most promise in triple-negative breast cancer, an aggressive subtype that lacks the three receptors typically targeted by other treatments: estrogen receptors, progesterone receptors, and HER2 protein. Triple-negative breast cancer represents about 10 to 15 percent of all breast cancer cases and tends to affect younger women and those with BRCA1 mutations more frequently. Because it doesn’t respond to hormone therapy or HER2-targeted drugs, treatment options have historically been limited to chemotherapy, surgery and radiation.
Clinical trials have demonstrated that adding a checkpoint inhibitor to chemotherapy before surgery, and continuing it after surgery, can significantly improve outcomes for patients with high-risk early-stage triple-negative breast cancer. In this early-stage setting, the benefit has been seen regardless of PD-L1 status. For advanced or metastatic triple-negative breast cancer, immunotherapy works best in tumors that express PD-L1, a protein that helps cancer cells hide from the immune system, so PD-L1 testing has become a routine part of evaluating metastatic triple-negative cases.
The Growing Focus on Early Detection
While advanced treatments like immunotherapy represent important progress, early detection remains the most effective tool for improving survival rates. Recent initiatives in Abu Dhabi have led to a substantial increase in screening rates, with public health campaigns driving more women to schedule mammograms and clinical examinations. When breast cancer is caught at stage I, the five-year survival rate exceeds 90 percent across most subtypes.
Screening recommendations vary by country, age and risk factors, but many guidelines now recommend that average-risk women begin regular mammograms at age 40, every one to two years. Those with family history, genetic mutations like BRCA1 or BRCA2, or previous chest radiation may need to begin screening earlier and include MRI alongside mammography. Dense breast tissue, common in younger women and certain populations, can make mammograms less effective, prompting the need for supplemental ultrasound or MRI.
Early detection also includes breast awareness: knowing how your breasts normally look and feel, and noticing changes in breast tissue, skin texture, or nipple discharge. Formal monthly self-examinations have not been shown to reduce mortality, but familiarity with your own breasts makes it easier to notice changes worth discussing promptly with a physician.
Accessing Comprehensive Breast Cancer Care
The effectiveness of any breast cancer treatment, including immunotherapy, depends heavily on accurate diagnosis and coordinated care across multiple specialties. Comprehensive breast centers bring together radiologists, pathologists, medical oncologists, surgical oncologists, radiation oncologists, and reconstructive surgeons under one framework. This multidisciplinary approach helps ensure that treatment plans consider all available options and are tailored to each patient’s disease characteristics and personal circumstances.
Cleveland Clinic Abu Dhabi’s Breast Health & Cancer Program exemplifies this model, offering services from initial screening through complex reconstruction. Patients requiring advanced treatment modalities can access cancer immunotherapy treatment in abu dhabi alongside traditional therapies, robotic surgical techniques, and genetic counseling for high-risk individuals. The integration of these services within a single program can reduce delays and help diagnostic findings directly inform treatment decisions.
Genetic testing has become particularly important as it identifies women who carry mutations that dramatically increase breast cancer risk. According to the NCI (National Cancer Institute), women with BRCA1 mutations face a 55 to 72 percent lifetime risk of breast cancer, while BRCA2 carriers face a 45 to 69 percent risk. Identifying these mutations early allows for enhanced surveillance, preventive measures, and informed decisions about risk-reducing surgeries.
What to Expect During Immunotherapy
For patients who are candidates for immunotherapy, the treatment typically involves intravenous infusions given every three to six weeks, depending on the drug and schedule. In early-stage triple-negative breast cancer, immunotherapy is usually given with chemotherapy for about six months before surgery and then continued on its own after surgery, for a total of about a year. Side effects differ markedly from traditional chemotherapy because immunotherapy activates rather than suppresses the immune system.
Common side effects include fatigue, skin reactions, and flu-like symptoms. More significantly, an overactive immune response can sometimes attack healthy tissue, causing inflammation in the lungs, liver, intestines, or endocrine glands. These immune-related adverse events require careful monitoring and may need treatment with corticosteroids to dampen the immune response. Most side effects are manageable when caught early, but some can be serious, and effects on hormone-producing glands such as the thyroid can be permanent and require lifelong hormone replacement. Open communication between patient and care team is essential.
Not every patient responds to immunotherapy, and researchers continue working to identify biomarkers beyond PD-L1 expression that can predict response. Tumor mutational burden, the presence of tumor-infiltrating lymphocytes, and specific genetic signatures all appear to influence outcomes. As testing becomes more sophisticated, patient selection is expected to become more precise.
The Broader Treatment Landscape
Immunotherapy represents one piece of a comprehensive treatment strategy. For hormone receptor-positive breast cancer, which accounts for about 70 percent of cases, endocrine therapy remains the primary systemic treatment. For HER2-positive disease, targeted therapies that block the HER2 protein have transformed outcomes since their introduction. Surgery, whether breast-conserving lumpectomy or mastectomy, continues to play a central role, with reconstruction options ranging from implant-based techniques to autologous tissue transfer using the patient’s own tissue.
Radiation therapy has also advanced significantly, with techniques like accelerated partial breast irradiation reducing treatment time from several weeks to about one week for select patients. Intraoperative radiation, delivered during surgery itself, offers another option for carefully selected low-risk cases.
Moving Forward with Prevention and Care
The evolution of breast cancer treatment, including the integration of immunotherapy, underscores the importance of both early detection and access to specialized care. Women in the UAE benefit from a healthcare infrastructure that increasingly emphasizes cancer prevention, early diagnosis, and treatment innovation. Staying current with screening recommendations, understanding personal risk factors, and seeking care from multidisciplinary teams when diagnosis occurs all contribute to better outcomes.
As research continues, immunotherapy is being studied in more breast cancer subtypes, and combination strategies pairing multiple immune-based approaches are under investigation. For now, the treatment offers meaningful benefit to a specific patient population, and its availability in the region represents an important advancement in local cancer care capabilities.
For a broader overview of immunotherapy research, see this MedicalResearch.com overview of immunotherapy for triple-negative breast cancer.
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Some links are sponsored. MedicalResearch.com and Eminent Domains Inc. do not warrant or endorse products or claims made by third party links. Always seek the advice of your physician or other qualified health provider and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on October 28, 2026 by Marie Benz MD FAAD